Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics, Inc. (Nasdaq: BNGO) presented advancements in optical genome mapping (OGM) during the AGBT 2023 workshop, emphasizing its potential to replace traditional methods for structural variant (SV) detection. Collaborating with NVIDIA, they showcased a new compute solution for high-throughput OGM analysis. Key presentations highlighted OGM's effectiveness in identifying undetected SVs relevant to rare diseases. Additionally, Bionano launched the Innovator Research Grant to promote research utilizing OGM technology. These developments aim to enhance genome analysis resolution and sensitivity in clinical and translational research.

Bionano Genomics, Inc. (BNGO) held its inaugural Strategy Day on February 2, 2023, at the Nasdaq MarketSite in New York City, featuring key executives discussing growth strategies, financial goals, and product development. The event included panels with experts in optical genome mapping (OGM), focusing on its applications in cancer and genetic disease research. Bionano aims to enhance cytogenetic analysis through OGM, targeting segments like cell bioprocessing and cancer research. The company is working on product launches and strategies to increase OGM adoption, with a focus on regulatory approvals and reimbursement for OGM-based tests.

Bionano Genomics recently concluded its 2023 Symposium, featuring over 3,000 registrants from 114 countries. Average daily attendance rose by 32% to 750 participants. The event included 31 oral presentations and 69 scientific posters highlighting the advancements of optical genome mapping (OGM) in genetic disease and cancer research. Key discussions emphasized OGM's ability to identify pathogenic variants overlooked by traditional methods, outperform legacy techniques, and streamline workflows. Presenters showcased how OGM enhances sample analysis and offers significant cost efficiencies, positioning it as a transformative tool in genomic research.

Bionano Laboratories has launched the OGM-Dx™ HemeOne™, a laboratory-developed test utilizing optical genome mapping (OGM) to identify structural variants in hematological malignancies. This test provides a more efficient workflow compared to traditional cytogenetic methods for detecting pathogenic variants in conditions like Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia. OGM-Dx HemeOne is the second such test from Bionano, following the introduction of an LDT for facioscapulohumeral muscular dystrophy in September 2022. The company emphasizes that this innovation supports oncologists in tailoring therapy for patients diagnosed with hematological cancers.

Bionano Genomics (BNGO) announced the launch of several new products enhancing its optical genome mapping (OGM) workflow. The Bionano Prep SP-G2 kit improves gDNA quality and throughput. The Bionano Prep Direct Label and Stain-G2 kit boosts reagent stability and speeds up DNA labeling, reducing turnaround time. Upgrades to the Saphyr Chip G3.3 and software versions enhance evaporation control and allow higher sample processing per week. These advancements aim to meet customer feedback, support high-volume genome analysis, and improve structural variant detection related to genetic diseases.

Bionano Genomics (BNGO) has announced the lineup for its upcoming virtual Symposium 2023, scheduled from January 23 to 26, 2023. The event will feature 30 oral presentations from 27 different customers, showcasing advancements in optical genome mapping (OGM) within genetic disease, cancer research, and cell bioprocessing. Attendees can participate in live panels and view 34 scientific posters. The CEO highlighted the event as a platform for collaboration and knowledge sharing in the OGM community. The company has reported significant workflow improvements, enhancing OGM's applicability in clinical research.

Bionano Genomics, Inc. (BNGO) released an interim report on its ongoing clinical trial for the prenatal genetic disease testing program. The study evaluated 200 samples from 123 unique cases across 9 sites. Key findings include:

• 56% of cases showed comparable results between the OGM analysis and two standard tests.
• 100% concordance with standard care for all samples and variant calls.
• 100% site-to-site reproducibility for analytical quality control.

The trial aims to position OGM as a cost-effective alternative in prenatal diagnostics, revealing promising results and potential next steps.

Bionano Genomics (BNGO) announced a collaboration with NVIDIA to create an acceleration platform for its optical genome mapping (OGM) workflow. This partnership aims to enhance data processing speed while minimizing costs related to secondary OGM data analysis. The platform is expected to support high-throughput workflows, processing up to 96 cancer workflows or over 300 whole genomes weekly. Bionano will showcase the solution at the AGBT General Meeting on February 6-9, 2023. The initiative is part of Bionano's strategy to expand into new research areas and improve healthcare outcomes.

Bionano Genomics (Nasdaq: BNGO) announced a study validating optical genome mapping (OGM) for identifying homologous recombination deficiency (HRD) in breast cancer samples. Published research indicates that OGM detected HRD effectively, showcasing superior sensitivity compared to whole genome sequencing (WGS). The study, conducted by Institut Curie on 15 triple negative breast carcinoma samples, highlights OGM's potential for capturing significant genomic alterations that WGS may miss. This advancement may enable better patient selection for PARP inhibitor treatments, potentially enhancing therapeutic outcomes.